Omnicell

OMCL

Market cap $1.62B

The consensus price target hints at a 30.9% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference.

Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies.

The consensus price target hints at a 34.5% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?

Five robotics-driven stocks - PATH, EMR, TRMB, OMCL and LECO - are set to gain traction heading into late 2025.

Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two stocks offers value investors a better bang for their buck right now?

Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

It scored not one, but two beats on analyst estimates for its third-quarter performance. This, despite a slight year-over-year decline in adjusted profitability.